Literature DB >> 6469882

The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid.

R Wise, S A Bennett, J Dent.   

Abstract

The pharmacokinetics of a new orally absorbed pro-drug of cefuroxime were compared with those of co-administered amoxycillin and clavulanic acid in six healthy male volunteers. Doses of 600 mg of acetoxyethyl cefuroxime and 500 mg amoxycillin plus 250 mg clavulanic acid were each administered for ten doses 8 hourly. Tissue penetration after the first dose of the antibiotic was estimated by a cantharides blister method. The faecal flora of the volunteers was studied throughout the study. The pharmacokinetics of cefuroxime and amoxycillin were very similar, peak levels of about 6.4 mg/l being found between 2 and 2.5 h after administration. The peak serum level of clavulanic acid was 4.3 mg/l at 1.25 h after administration. The serum half-lives were about 1.1 h for all three agents. No drug accumulation occurred over the four days of the study. The 0-8 h urinary recovery of cefuroxime was 30%. All three agents penetrated the blister fluid rapidly, the main peak levels being 64% of the peak serum level for cefuroxime, 72% for amoxycillin and 55% for clavulanic acid. The incidence of side effects was similar for each regimen. Three volunteers having diarrhoea after cefuroxime showed significant alterations in their bowel flora.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6469882     DOI: 10.1093/jac/13.6.603

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  21 in total

Review 1.  Pharmacokinetics and tissue concentrations of cefuroxime.

Authors:  T B Vree; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

2.  Pharmacokinetics and tissue penetration of ceftibuten.

Authors:  R Wise; K Nye; P O'Neill; M Wostenholme; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.

Authors:  H Lode; C Müller; K Borner; C E Nord; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 4.  Comparative pharmacokinetics of the new oral cephalosporins.

Authors:  H Lode; M Fassbender; T Schaberg; K Borner; P Koeppe
Journal:  Drugs       Date:  1994       Impact factor: 9.546

5.  Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers.

Authors:  P O'Neill; K Nye; G Douce; J Andrews; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

6.  Comparative trial of cefuroxime axetil in recurrent urinary tract infections illustrating importance of 6-week follow-up.

Authors:  W Brumfitt; J M Hamilton-Miller; G W Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

7.  Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil.

Authors:  M T Borin; G S Hughes; C R Spillers; R K Patel
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

Review 9.  Adverse reactions and interactions with newer cephalosporin and cephamycin antibiotics.

Authors:  S R Norrby
Journal:  Med Toxicol       Date:  1986 Jan-Feb

10.  Comparison of oral treatment of uncomplicated urogenital and rectal gonorrhoea with cefuroxime axetil ester or clavulanic acid potentiated amoxycillin (Augmentin).

Authors:  R Schift; J van Ulsen; M C Ansink-Schipper; T van Joost; M F Michel; R K Woudstra; E Stolz
Journal:  Genitourin Med       Date:  1986-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.